Atypical hemolytic uremic syndrome responsive to steroids and intravenous immune globulin

Tanya Watt, Barry Warshaw, Howard M. Katzenstein

Research output: Contribution to journalArticle

11 Scopus citations


Atypical hemolytic uremic syndrome remains a challenge to diagnose and treat, with significant acute morbidity and risk for progression to end stage renal disease. Treatment strategies center on plasma exchange but do not necessarily affect the progression of disease. We report the case of a patient with atypical HUS resulting from a mutation in the complement pathway who responded to treatment with steroids and IVIG, therefore avoiding transfusion or plasma exchange.

Original languageEnglish (US)
Pages (from-to)90-91
Number of pages2
JournalPediatric Blood and Cancer
Issue number1
StatePublished - Jul 15 2009



  • Anemia
  • Hemolytic
  • Steroids
  • Uremic

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this